SyntheticMR develops and markets software solutions for Magnetic Resonance Imaging (MRI). The company has developed SyMRI which delivers multiple adjustable contrast images and quantitative data from a single 5-minute scan. By combining SyntheticMR’s ability to provide brain tissue characterization and Combinostics’ segmentation algorithms, the two together meet customer demand for a combined capability, particularly related to neurodegenerative diseases such as MS and Dementia, they state.

“With quantification of brain characteristics combined with AI-driven statistical analysis, we gain an ability to provide an insight into the state of the brain like no other,” says Combinostics’ CEO Lennart Thurfjell.

Related article

Interview: Using AI to improve early diagnosis

Finnish Combinostics is aiming to expand its platform for early detection of neurodegeneration into new markets and sees an increasing demand for technologies such as theirs. Combinostics was founded in Tampere in 2014 and its technology is built on research at the VTT Technical Research Centre of Finland, studying AI and machine learning for diagnostics. […]


Combinostics’ business model is primarily based on annual subscriptions and has an established base of ARR customers. This is expected to strengthen the ability of SyntheticMR to pursue plans in the same direction with subscribing customers. This is realized through the platform provided by Combinostics via a cloud solution. Conversely, there are customer groups that require on-site installation and there the companies complement each other as both solutions intend to be delivered on the respective platform.ber

Related article

Navigating the Financial Landscape: Merger

Combining the strengths of two companies is a way to position against competitors and also become more resilient to a fluctuating financial market.


“We believe that the expertise and commitment of the employees within Combinostics are central to Combinostics’ success and it is our strong belief that there is good potential to realize Combinostics’ underlying value and growth with a common ambition,” says SyntheticMR’s CEO Ulrik Harrysson.